Fred Hutch Cancer Center is leading the newly launched Vanguard Study, a national study of a new type of blood test that screens for several different cancers called multi-cancer detection (MCD) tests ...

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that patient enrollment has begun ...

A clinical trial is launching to test the effectiveness of new tests that aim to detect genetic signatures of cancer in the ...

As technology continues to evolve, bringing AI, advanced imaging, and novel sampling techniques into routine practice, the ...

Key Takeaways GLP-1 drugs might increase a person’s risk of severe acid refluxPeople with type 2 diabetes taking GLP-1 drugs ...

Invikafusp alfa, a dual T-cell agonist targeting subsets of tumor-infiltrating lymphocytes, can elicit responses in patients with heavily pretreated gastrointestinal cancers, according to research ...

TissueCypher is a laboratory test that can help predict the risk of developing esophageal cancer in patients diagnosed with Barrett’s esophagus (BE).

Half of all cancer deaths worldwide are attributable to modifiable risk factors, according to The Cancer Atlas.

A capsule-sponge test may help identify patients with Barrett’s esophagus who are at low risk for dysplasia or esophageal ...

The Vanderbilt community will honor First Sergeant Lawrence “Gator” Howard Jr., a decorated Army veteran, with a plaque ...

Further data could back zanidatamab as advanced treatment for HER2-positive advanced gastroesophageal adenocarcinoma.

A test developed by a Madison company to better track cancer DNA in the blood stream will now be covered by Medicare.